[Evidence-based therapy for myelodysplastic syndrome].
Toyama
Kaoru
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019317:Evidence-Based Medicine; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000628:therapy*; D011379:Prognosis; D024482:Vitamin K 2 / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D024482:Vitamin K 2; D016179:Granulocyte Colony-Stimulating Factor